An Evaluation of the Duration of Oral Anticoagulant Use Among Patients Undergoing Endovascular Treatment of Nonthrombotic Iliac Vein Lesions

作者全名："Peng, Minyong; Nie, Chengli; Chen, Jiangwei; Li, Chao; Huang, Wen"

作者地址："[Peng, Minyong; Nie, Chengli; Chen, Jiangwei; Li, Chao; Huang, Wen] Chongqing Med Univ, Affiliated Hosp 1, Dept Vasc Surg, Chongqing 400010, Peoples R China"

通信作者："Huang, W (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Vasc Surg, Chongqing 400010, Peoples R China."

来源：ANNALS OF VASCULAR SURGERY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001166429800001

JCR分区：Q3

影响因子：1.5

年份：2024

卷号：100

期号：　

开始页：110

结束页：119

文献类型：Article

关键词：　

摘要："Background: This study aimed to compare clinical outcomes associated with the duration of postoperative direct oral anticoagulant (DOACs) therapy in patients with nonthrombotic iliac vein lesions. Methods: We retrospectively analyzed 176 consecutive patients who underwent stenting for nonthrombotic iliac vein lesions between March 2018 and December 2021. In total, 99 and 77 patients were discharged on a 3-month and >3-month regimen of DOAC therapy, respectively. The primary cumulative endpoint was a composite of thrombotic complications, bleeding complications, primary patency, primary-assisted patency, and secondary patency within 1 year. Results: Patients undergoing 3-month and >3-month DOAC therapy were similar in age, sex, lesion site, symptoms, and average stent diameter and length. Upon multivariate analysis, the primary cumulative endpoint did not differ between the 2 groups (hazard ratio [HR]: 1.18; 95% confidence interval [CI]: 0.42-3.30; P = 0.76). Moreover, the primary patency at 1 year did not differ between the groups (HR: 1.50; 95% CI: 0.14-16.54; P = 0.74). Furthermore, there were no discernible differences in the secondary endpoints of bleeding complications (HR: 0.66; 95% CI: 0.22-1.96; P = 0.45) or thrombotic complications (HR: 1.79; 95% CI: 0.55-5.80; P = 0.34) between the groups. Conclusions: The 3-month regimen of DOAC therapy showed a similar risk of postoperative thrombosis and bleeding when compared to longer DOAC therapy durations over the course of 1 year following endovascular intervention. This could be a preferred option for patients with a higher estimated bleeding risk after venous stenting."

基金机构：　

基金资助正文：